世界の動脈塞栓術市場(~2026年):製品別(塞栓剤(マイクロスフィア、液体塞栓剤、コイル)、マイクロカテーテル)、疾患別(腫瘍、血管、動脈瘤、泌尿器、腎臓)、処置別(TACE、TARE)、エンドユーザー別(病院、クリニック、ASC)

■ 英語タイトル:Embolotherapy Market by Product (Embolic Agents (Microspheres, Liquid Embolic Agents, Coil), Microcatheters), Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology), Procedure (TACE, TARE), Enduser (Hospital, Clinics, ASC) - Global Forecast to 2026

調査会社MarketsandMarkets社が発行したリサーチレポート(データ管理コード:MD7279)■ 発行会社/調査会社:MarketsandMarkets
■ 商品コード:MD7279
■ 発行日:2021年5月20日
■ 調査対象地域:グローバル
■ 産業分野:医療
■ ページ数:222
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界の動脈塞栓術市場(~2026年):製品別(塞栓剤(マイクロスフィア、液体塞栓剤、コイル)、マイクロカテーテル)、疾患別(腫瘍、血管、動脈瘤、泌尿器、腎臓)、処置別(TACE、TARE)、エンドユーザー別(病院、クリニック、ASC)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

マーケッツアンドマーケッツ社は、世界の動脈塞栓術市場規模が2021年34億ドルから2026年50億ドルまで、年平均8.0%成長すると予測しています。本調査レポートでは、動脈塞栓術の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(塞栓剤、塞栓コイル、塞栓プラグシステム、デタッチャブルバルーン、マイクロカテーテル)分析、用途別(腫瘍、末梢血管疾患、神経、泌尿器・腎臓、消化器疾患)分析、処置別(肝動脈塞栓術(TAE)、肝動脈塞栓術、肝動脈化学塞栓術(TACE))分析、エンドユーザー別(病院・クリニック、外来手術センター、その他)分析、地域別分析、競争状況、企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の動脈塞栓術市場規模:製品別(塞栓剤、塞栓コイル、塞栓プラグシステム、デタッチャブルバルーン、マイクロカテーテル)
・世界の動脈塞栓術市場規模:用途別(腫瘍、末梢血管疾患、神経、泌尿器・腎臓、消化器疾患)
・世界の動脈塞栓術市場規模:処置別(肝動脈塞栓術(TAE)、肝動脈塞栓術、肝動脈化学塞栓術(TACE))
・世界の動脈塞栓術市場規模:エンドユーザー別(病院・クリニック、外来手術センター、その他)
・世界の動脈塞栓術市場規模:地域別
・競争状況
・企業情報

“The global embolotherapy market is valued at USD 3.4 billion in 2021 and is expected to reach USD 5.0 billion by 2026, at a CAGR of 8.0% during the forecast period.”
The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Moreover, increasing demand for minimally invasive procedures, favorable reimbursement scenario, and new product launches in the market are further supporting the growth of the market over the forecast period. However, stringent regulatory frameworks for product commercialization and the strong market positioning of alternative treatments are expected to limit the optimal adoption of embolotherapy devices during the forecast period.

“The cancer segment, by application, accounted for the largest share of the embolotherapy market in 2020”
In terms of application, embolotherapy market is classified into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders. The high success rate and less post-operative complication rate associated with embolotherapy procedures coupled with the rising incidences of liver cancer and hepatocellular cancer are the key factors fueling the demand for embolotherapy devices for cancer disease indication. For instance, liver cancer is the fifth most common cancer in men and the ninth most common in women.

“The embolic agents segment, by product, is to register a significant growth rate owing to new product approvals”
Based on product, the embolotherapy market is broadly segmented into embolization coils (detachable coils and pushable coils), embolic agents (liquid embolic agents and microspheres), detachable balloons, embolic plug systems, and support devices (microcatheters and guidewires). The embolic agents segment is anticipated to register the highest growth over the forecast period owing to new product approvals and launches in the segment. For instance, in 2019, Terumo received the FDA Premarket Approval (PMA) for the ‘WEB Aneurysm Embolization System.’ Moreover, in 2018, Medtronic launched OptiSphere embolization spheres in the US as well as the Concerto 3D detachable coil system in Ireland.

“Increasing availability of reimbursements in most of developed countries to drive the segment growth of ambulatory surgical centers end user segment”
Based on end users, the embolotherapy market is segmented into hospitals and clinics, ambulatory surgery centers (ASCs), and other end users. The ambulatory surgery centers segment is projected to register the highest CAGR during the forecast period. The significant growth of this segment can be attributed to the growing adoption of minimally invasive surgical procedures, the increasing number of procedures in ambulatory surgery centers, and the greater availability of reimbursements for target procedures in the US and major European countries.

“The US market, by region, commanded the largest market share in 2020”
On the basis of region, the embolotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The US held the major share of the global embolotherapy market in 2018. Factors such as the favorable reimbursement scenario in the US, growing target patient population (CVDs, neurovascular diseases, cancer, and uterine fibroids), increasing preference for minimally invasive procedures, new product launches and technological advancements in embolotherapy devices, and the presence of key players in the region are driving the growth of the embolotherapy market in the US.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–45%, Tier 2–34%, and Tier 3– 21%
• By Designation: C-level–47%, Director-level–33%, and Others–20%
• By Region: North America–35%, Europe–32%, Asia Pacific–25%, Latin America–6%, and the Middle East & Africa–2%

Some of the prominent players in the embolotherapy market Boston Medical Corporation (US), Terumo Medical Systems (Japan), Medtronic (US), Johnson & Johnson (US), and Stryker Corporation (US). Other key players in the embolization therapy market include Sirtex Medical Limited (US), Abbott Laboratories (US), Acandis GmbH (Germany), Balt (France), Cook Medical (US), Kaneka Corporation (Japan), Penumbra, Inc. (US), Merit Medical Systems (US), Meril Life Sciences Pvt. Ltd. (India), Cardiva (US), Shape Memory Medical Inc. (US), Artio Medical Inc. (US), Rapid Medical (US), Emboline, Inc. (US), and IMbiotechnologies Ltd. (Canada), among others.

Research Coverage
This report studies the embolotherapy market based on product, procedure, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the embolotherapy market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the embolotherapy market
 Market Development: Comprehensive information on lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the embolotherapy market
 Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

*** レポート目次(コンテンツ)***

1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 31
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.3.2 YEARS CONSIDERED FOR THE STUDY 33
1.4 CURRENCY USED FOR THE STUDY 33
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.1.1 An indicative list of secondary sources 37
2.1.2 PRIMARY DATA 37
FIGURE 2 BREAKDOWN OF PRIMARIES: EMBOLOTHERAPY MARKET 38
2.2 MARKET ESTIMATION METHODOLOGY 38
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 39
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 39
2.2.2 PRODUCT-BASED MARKET ESTIMATION 40
FIGURE 4 MARKET SIZE ESTIMATION: EMBOLOTHERAPY MARKET 41
2.2.3 PRIMARY RESEARCH VALIDATION 41
2.3 DATA TRIANGULATION 42
FIGURE 5 DATA TRIANGULATION METHODOLOGY 42
2.4 RESEARCH ASSUMPTIONS 43
2.5 RESEARCH LIMITATIONS 43
3 EXECUTIVE SUMMARY 44
FIGURE 6 EMBOLOTHERAPY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION) 44
FIGURE 7 EMBOLOTHERAPY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION) 45
FIGURE 8 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION) 45
FIGURE 9 EMBOLOTHERAPY MARKET SHARE, BY END USER, 2021 VS. 2026 46
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE EMBOLOTHERAPY MARKET 47

4 PREMIUM INSIGHTS 48
4.1 EMBOLOTHERAPY: MARKET OVERVIEW 48
FIGURE 11 THE RISING INCIDENCE OF CHRONIC DISEASES IS A KEY FACTOR DRIVING MARKET GROWTH 48
4.2 GEOGRAPHIC ANALYSIS: NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, 2021 VS 2026, (USD MILLION) 49
FIGURE 12 THE EMBOLIC AGENTS SEGMENT WILL WITNESS HIGH GROWTH IN THE NORTH AMERICA MARKET IN 2026 49
4.3 EMBOLOTHERAPY MARKET, BY APPLICATION, 2021 VS 2026, (USD MILLION) 50
FIGURE 13 THE LIVER CANCER SUBSEGMENT OF THE ONCOLOGY APPLICATION IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 50
4.4 EMBOLOTHERAPY MARKET, BY REGION AND PROCEDURE 51
FIGURE 14 TRANSARTERIAL EMBOLIZATION (TAE) PROCEDURE SEGMENT TO HOLD A MAJOR SHARE OF THE ASIA PACIFIC MARKET 51
4.5 GEOGRAPHIC ANALYSIS: EMBOLOTHERAPY MARKET, BY END USER AND
REGION, 2021 VS. 2026 (USD MILLION) 51
FIGURE 15 AMBULATORY SURGICAL CENTERS SEGMENT TO WITNESS HIGH GROWTH IN EUROPE DURING THE FORECAST PERIOD 51
4.6 GEOGRAPHIC SNAPSHOT OF THE EMBOLOTHERAPY MARKET 52
FIGURE 16 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 17 EMBOLOTHERAPY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Growing target patient population 54
TABLE 1 PRIMARY INCIDENCE OF LIVER CANCER AMONG MEN
AND WOMEN (2005 VS. 2030) 54
TABLE 2 GERIATRIC POPULATION, BY REGION (2015 VS. 2030) 55
5.2.1.2 Rising patient preference for minimally invasive procedures 55
5.2.1.3 Funding & investments by government and private organizations 55
5.2.1.4 Technological advancements in embolotherapy devices 56
5.2.1.5 Favorable reimbursement scenario for minimally invasive surgeries 57
TABLE 3 MEDICAL REIMBURSEMENT CPT CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2021) 57
TABLE 4 MEDICAL REIMBURSEMENT MS-DRG CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2019) 58
5.2.2 RESTRAINTS 58
5.2.2.1 Lack of sufficient evidence & unfavorable regulatory scenario 58
5.2.2.2 Strong market positioning of alternative therapies 59
5.2.3 OPPORTUNITIES 60
5.2.3.1 Growth opportunities offered by emerging markets 60
5.2.3.2 Expanding applications of embolization devices 60
5.2.4 CHALLENGES 61
5.2.4.1 A dearth of skilled surgeons 61
5.2.4.2 High cost of embolization devices 61
5.3 VALUE CHAIN ANALYSIS 61
FIGURE 18 VALUE CHAIN ANALYSIS 62
5.4 ECOSYSTEM: EMBOLOTHERAPY MARKET 62
5.5 REGULATORY ANALYSIS 63
5.5.1 NORTH AMERICA 63
5.5.1.1 US 63
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION 63
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 64
5.5.1.2 Canada 64
TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 64
FIGURE 19 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 65
5.5.2 EUROPE 65
FIGURE 20 EUROPE: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES (MDR) 66
5.5.3 ASIA PACIFIC 67
5.5.3.1 Japan 67
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA) 67
5.5.3.2 China 68
TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES 68
5.5.3.3 India 69
5.6 IMPACT OF COVID-19 ON EMBOLOTHERAPY MARKET 70
TABLE 10 COVID-19 GUIDELINES FOR TRIAGE OF VASCULAR SURGERY PATIENTS 70
6 EMBOLOTHERAPY MARKET, BY PRODUCT 72
6.1 INTRODUCTION 73
TABLE 11 EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 73
6.2 EMBOLIC AGENTS 73
TABLE 12 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 74
TABLE 13 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY REGION,
2019–2026 (USD MILLION) 74
TABLE 14 EMBOLIC AGENTS, BY TYPE 75
6.2.1 LIQUID EMBOLIC AGENTS 75
6.2.1.1 Significant adoption of embolic coils due to their procedural benefits over liquid embolic agents is expected to restrict the market growth 75
TABLE 15 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2019–2026 (USD MILLION) 76
6.2.1.2 Embolotherapy market for liquid embolic agents, by application 76
TABLE 16 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY APPLICATION, 2019–2026 (USD MILLION) 76
6.2.1.3 Embolotherapy market for liquid embolic agents, by Procedure 77
TABLE 17 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY PROCEDURE, 2019–2026 (USD MILLION) 77
6.2.1.4 Embolotherapy market for liquid embolic agents, by end user 77
TABLE 18 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY END USER, 2019–2026 (USD MILLION) 77
6.2.2 MICROSPHERES 77
6.2.2.1 Preference for alternative procedures limits the growth of this market segment 77
TABLE 19 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY REGION,
2019–2026 (USD MILLION) 79
6.2.2.2 Embolotherapy market for microspheres, by application 79
TABLE 20 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY APPLICATION,
2019–2026 (USD MILLION) 79
6.2.2.3 Embolotherapy market for microspheres, by Procedure 80
TABLE 21 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY PROCEDURE,
2019–2026 (USD MILLION) 80
6.2.2.4 Embolotherapy market for microspheres, by end user 80
TABLE 22 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY END USER,
2019–2026 (USD MILLION) 80
6.3 EMBOLIZATION COILS 80
TABLE 23 EMBOLIC COILS OFFERED BY MAJOR MARKET PLAYERS 81
TABLE 24 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 81
TABLE 25 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY REGION,
2019–2026 (USD MILLION) 82
6.3.1 DETACHABLE COILS 82
6.3.1.1 Detachable coils can be retracted and redeployed a number of times until satisfactory placement is reached, which is a key advantage of this product segment 82
TABLE 26 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY REGION,
2019–2026 (USD MILLION) 83
6.3.1.2 Embolotherapy market for detachable coils, by application 83
TABLE 27 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY APPLICATION, 2019–2026 (USD MILLION) 83
6.3.1.3 Embolotherapy market for detachable coils, by Procedure 84
TABLE 28 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY PROCEDURE,
2019–2026 (USD MILLION) 84
6.3.1.4 Embolotherapy market for detachable coils, by end user 84
TABLE 29 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY END USER,
2019–2026 (USD MILLION) 84
6.3.2 PUSHABLE COILS 84
6.3.2.1 The use of pushable coils increases the risk of non-target vascular blockages, thus restricting their use in various applications 84
TABLE 30 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY REGION,
2019–2026 (USD MILLION) 85
6.3.2.2 Embolotherapy market for pushable coils, by application 85
TABLE 31 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY APPLICATION,
2019–2026 (USD MILLION) 85
6.3.2.3 Embolotherapy market for pushable coils, by Procedure 86
TABLE 32 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY PROCEDURE,
2019–2026 (USD MILLION) 86
6.3.2.4 Embolotherapy market for pushable coils, by end user 86
TABLE 33 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY END USER,
2019–2026 (USD MILLION) 86
6.4 EMBOLIC PLUG SYSTEMS 86
TABLE 34 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY REGION, 2019–2026 (USD MILLION) 87
6.4.1 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION 87
TABLE 35 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION, 2019–2026 (USD MILLION) 87
6.4.2 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE 87
TABLE 36 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE, 2019–2026 (USD MILLION) 87
6.4.3 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER 88
TABLE 37 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER, 2019–2026 (USD MILLION) 88
6.5 DETACHABLE BALLOONS 88
6.5.1 ADVERSE EVENTS ASSOCIATED WITH THE USE OF DETACHABLE BALLOONS SUCH AS BALLOON RUPTURE, FAILURE, OR SHRINKAGE MAY LIMIT THE UTILIZATION OF THIS EMBOLIC DEVICE 88
TABLE 38 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY REGION, 2019–2026 (USD MILLION) 89
6.5.2 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION 89
TABLE 39 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION, 2019–2026 (USD MILLION) 89
6.5.3 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE 89
TABLE 40 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE, 2019–2026 (USD MILLION) 89
6.5.4 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER 90
TABLE 41 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER, 2019–2026 (USD MILLION) 90
6.6 SUPPORT DEVICES 90
TABLE 42 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 90
TABLE 43 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY REGION,
2019–2026 (USD MILLION) 91
6.6.1 MICROCATHETERS 91
6.6.1.1 Advancements and regulatory approvals in microcatheter technologies are expected to result in their wider adoption 91
TABLE 44 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY REGION,
2019–2026 (USD MILLION) 91
6.6.1.2 Embolotherapy market for microcatheters, by application 92
TABLE 45 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY APPLICATION,
2019–2026 (USD MILLION) 92
6.6.1.3 Embolotherapy market for microcatheters, by Procedure 92
TABLE 46 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY PROCEDURE,
2019–2026 (USD MILLION) 92
TABLE 47 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY END USER,
2019–2026 (USD MILLION) 93
6.6.2 GUIDEWIRES 93
6.6.2.1 Rising adoption of guidewires among medical professionals owing to their procedural benefits is expected to drive market growth 93
TABLE 48 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY REGION,
2019–2026 (USD MILLION) 93
6.6.2.2 Embolotherapy market for guidewires, by application 94
TABLE 49 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY APPLICATION,
2019–2026 (USD MILLION) 94
6.6.2.3 Embolotherapy market for guidewires, by Procedure 94
TABLE 50 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY PROCEDURE,
2019–2026 (USD MILLION) 94
6.6.2.4 Embolotherapy market for guidewires, by end user 95
TABLE 51 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY END USER,
2019–2026 (USD MILLION) 95
7 EMBOLOTHERAPY MARKET, BY APPLICATION 96
7.1 INTRODUCTION 97
TABLE 52 EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026 97
7.2 ONCOLOGY 97
TABLE 53 EMBOLOTHERAPY MARKET FOR ONCOLOGY, BY TYPE, 2019–2026 98
TABLE 54 EMBOLOTHERAPY MARKET FOR CANCER, BY REGION, 2019–2026 98
7.2.1 LIVER CANCER 98
7.2.1.1 The rising prevalence of liver cancer is expected to drive segment growth 98
TABLE 55 EMBOLOTHERAPY MARKET FOR LIVER CANCER, BY REGION,
2019–2026 (USD MILLION) 99
7.2.2 KIDNEY CANCER 99
7.2.2.1 Preoperative kidney tumor embolization in the treatment of kidney cancer drives the segment growth 99
TABLE 56 EMBOLOTHERAPY MARKET FOR KIDNEY CANCER, BY REGION,
2019–2026 (USD MILLION) 100
7.2.3 LUNG CANCER 100
7.2.3.1 Use of arterial embolotherapy in patients with primary lung cancer to drive the segment growth 100
TABLE 57 EMBOLOTHERAPY MARKET FOR LUNG CANCER, BY REGION,
2019–2026 (USD MILLION) 101
7.2.3.2 The increasing prevalence of breast cancer is a key factor in the higher adoption of embolotherapy among surgeons 101
TABLE 58 EMBOLOTHERAPY MARKET FOR BREAST CANCER, BY REGION,
2019–2026 (USD MILLION) 101
7.2.4 OTHER CANCERS 102
TABLE 59 EMBOLOTHERAPY MARKET FOR OTHER CANCERS, BY REGION,
2019–2026 (USD MILLION) 102
7.3 PERIPHERAL VASCULAR DISEASES 102
7.3.1 RISING ADOPTION OF VASCULAR PLUGS IS A KEY FACTOR DRIVING MARKET GROWTH 102
TABLE 60 EMBOLOTHERAPY MARKET FOR PERIPHERAL VASCULAR DISEASES,
BY REGION, 2019–2026 (USD MILLION) 103
7.4 NEUROLOGY 103
TABLE 61 EMBOLOTHERAPY MARKET FOR NEUROLOGY, BY TYPE, 2019–2026 104
TABLE 62 EMBOLOTHERAPY MARKET FOR NEUROLOGY, BY REGION,
2019–2026 (USD MILLION) 104
7.4.1 BRAIN ANEURYSM 104
7.4.1.1 Limited availability of reimbursements across major markets may hinder the market growth 104
TABLE 63 EMBOLOTHERAPY MARKET FOR BRAIN ANEURYSM, BY REGION,
2019–2026 (USD MILLION) 105
7.4.2 CEREBRAL ARTERIOVENOUS MALFORMATION 105
7.4.2.1 Side effects associated with AVM embolization procedures may restrict market growth to a certain extent 105
TABLE 64 EMBOLOTHERAPY MARKET FOR CEREBRAL ARTERIOVENOUS MALFORMATION, BY REGION, 2019–2026 (USD MILLION) 106
7.5 UROLOGY & NEPHROLOGY 106
TABLE 65 EMBOLOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY TYPE,
2019–2026 (USD MILLION) 107
TABLE 66 EMBOLOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY REGION, 2019–2026 (USD MILLION) 107
7.5.1 BENIGN PROSTATIC HYPERPLASIA 107
7.5.1.1 Risks associated with traditional surgery will make patients opt for PAE treatment 107
TABLE 67 EMBOLOTHERAPY MARKET FOR BENIGN PROSTATIC HYPERPLASIA,
BY REGION, 2019–2026 (USD MILLION) 108
7.5.1.2 Advantages offered by the UFE over other techniques is a key factor driving market growth 108
TABLE 68 EMBOLOTHERAPY MARKET FOR UTERINE FIBROIDS, BY REGION,
2019–2026 (USD MILLION) 108
7.5.2 OTHER UROLOGY & NEPHROLOGY APPLICATIONS 109
7.5.2.1 Safety and minimal complication with the use of TAE in this segment will drive the market growth 109
TABLE 69 EMBOLOTHERAPY MARKET FOR OTHER UROLOGY & NEPHROLOGY APPLICATIONS, BY REGION, 2019–2026 (USD MILLION) 109
7.6 GASTROINTESTINAL DISORDERS 110
7.6.1 EMBOLIZATION IS A WIDELY ADOPTED PROCEDURE USED TO TREAT LGIB AND UGIB 110
TABLE 70 EMBOLOTHERAPY MARKET FOR GASTROINTESTINAL DISORDERS,
BY REGION, 2019–2026 (USD MILLION) 110

8 EMBOLOTHERAPY MARKET, BY PROCEDURE 111
8.1 INTRODUCTION 112
TABLE 71 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 112
8.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) 112
8.2.1 THE GROWTH OF THIS SEGMENT IS LARGELY DRIVEN DUE TO THE INCREASING INCIDENCE OF UTERINE FIBROIDS & VASCULAR LESIONS 112
TABLE 72 TRANSCATHETER ARTERIAL EMBOLIZATION MARKET, BY REGION,
2019–2026 (USD MILLION) 113
8.3 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION (TARE)/SELECTIVE INTERNAL RADIATION THERAPY (SIRT) 114
8.3.1 BETTER CLINICAL OUTCOMES & INCREASED CANCER SURVIVAL RATE SUPPORTS THE GROWTH OF THIS SEGMENT 114
TABLE 73 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION MARKET, BY REGION, 2019–2026 (USD MILLION) 115
8.4 TRANSARTERIAL CHEMOEMBOLIZATION (TACE) 115
8.4.1 TACE CAN BE USED TO TREAT TUMORS THAT ARE RELATIVELY LARGER IN SIZE, WHICH CANNOT BE EASILY TREATED BY TUMOR ABLATION 115
TABLE 74 TRANSARTERIAL CHEMOEMBOLIZATION MARKET, BY REGION, 2019–2026 116
9 EMBOLOTHERAPY MARKET, BY END USER 117
9.1 INTRODUCTION 118
TABLE 75 EMBOLOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION) 118
9.2 HOSPITALS AND CLINICS 118
9.2.1 RISING INCIDENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH 118
TABLE 76 EMBOLOTHERAPY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2019–2026 (USD MILLION) 119
9.3 AMBULATORY SURGERY CENTERS 119
9.3.1 INCREASING AVAILABILITY OF REIMBURSEMENTS TO DRIVE THE ADOPTION OF EMBOLOTHERAPY PRODUCTS IN ASCS 119
TABLE 77 EMBOLOTHERAPY MARKET FOR AMBULATORY SURGERY CENTERS,
BY REGION, 2019–2026 (USD MILLION) 120
9.4 OTHER END USERS 120
TABLE 78 EMBOLOTHERAPY MARKET FOR OTHER END USERS, BY REGION,
2019–2026 (USD MILLION) 120
10 EMBOLOTHERAPY MARKET, BY REGION 121
10.1 INTRODUCTION 122
TABLE 79 EMBOLOTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION) 122
10.2 NORTH AMERICA 123
FIGURE 21 NORTH AMERICA: EMBOLOTHERAPY MARKET SNAPSHOT 123
TABLE 80 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 124
TABLE 81 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 124
TABLE 82 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS,
BY TYPE, 2019–2026 (USD MILLION) 124
TABLE 83 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 84 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 85 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 125
TABLE 86 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 126
TABLE 87 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 126
10.2.1 US 127
10.2.1.1 Increasing R&D investments in the country drives the market growth 127
TABLE 88 US: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 127
TABLE 89 US: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 128
TABLE 90 US: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 128
TABLE 91 US: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 128
10.2.2 CANADA 129
10.2.2.1 The rising prevalence of cancer supports market growth in Canada 129
TABLE 92 CANADA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 129
TABLE 93 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 94 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 95 CANADA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 130
10.3 EUROPE 131
TABLE 96 EUROPE: EMBOLOTHERAPY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 131
TABLE 97 EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 131
TABLE 98 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 132
TABLE 99 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 132
TABLE 100 EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 101 EUROPE: EMBOLOTHERAPY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 133
TABLE 102 EUROPE: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 133
TABLE 103 EUROPE: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 134
10.3.1 GERMANY 134
10.3.1.1 Germany is the fastest growing market in Europe 134
TABLE 104 GERMANY: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 135
TABLE 105 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 106 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 135
TABLE 107 GERMANY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 136
10.3.2 UK 136
10.3.2.1 The rising geriatric population and the high incidence of chronic diseases support market growth in the UK 136
TABLE 108 UK: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 137
TABLE 109 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 137
TABLE 110 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 137
TABLE 111 UK: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 138
10.3.3 FRANCE 138
10.3.3.1 The growing geriatric population coupled with the increasing number of target surgeries to support market growth in France 138
TABLE 112 FRANCE: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 138
TABLE 113 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 114 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 115 FRANCE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 139
10.3.4 SPAIN 140
10.3.4.1 Increasing government funding for research to support market growth 140
TABLE 116 SPAIN: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 140
TABLE 117 SPAIN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 140
TABLE 118 SPAIN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 119 SPAIN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 141
10.3.5 ITALY 141
10.3.5.1 Rising awareness activities to support market growth 141
TABLE 120 ITALY: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 142
TABLE 121 ITALY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 142
TABLE 122 ITALY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 142
TABLE 123 ITALY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 143
10.3.6 REST OF EUROPE 143
TABLE 124 REST OF EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 144
TABLE 125 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS,
BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 126 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 127 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2019–2026 (USD MILLION) 145
10.4 ASIA PACIFIC 145
FIGURE 22 ASIA PACIFIC: EMBOLOTHERAPY MARKET SNAPSHOT 146
TABLE 128 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 147
TABLE 129 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 147
TABLE 130 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 147
TABLE 131 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 132 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 133 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 149
TABLE 134 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 149
TABLE 135 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 150
10.4.1 JAPAN 150
10.4.1.1 Presence of universal healthcare reimbursement scenario and growing geriatric population—key factors driving market growth 150
TABLE 136 JAPAN: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 151
TABLE 137 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 138 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 139 JAPAN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 152
10.4.2 CHINA 152
10.4.2.1 Increasing patient pool and government initiatives for healthcare development supports market growth 152
TABLE 140 CHINA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 153
TABLE 141 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 153
TABLE 142 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 153
TABLE 143 CHINA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 154
10.4.3 INDIA 154
10.4.3.1 Ongoing modernization and infrastructure development in India to support the market growth for embolotherapy 154
TABLE 144 INDIA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 155
TABLE 145 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 155
TABLE 146 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 155
TABLE 147 INDIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 156
10.4.4 SOUTH KOREA 156
10.4.4.1 Rising R&D and promising clinical trials in the country to positively impact market growth 156
TABLE 148 SOUTH KOREA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 156
TABLE 149 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 157
TABLE 150 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 157
TABLE 151 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 157
10.4.5 AUSTRALIA 158
10.4.5.1 Rising research investments and awareness campaigns are the key factors supporting market growth in Australia 158
TABLE 152 AUSTRALIA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 158
TABLE 153 AUSTRALIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 154 AUSTRALIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 159
TABLE 155 AUSTRALIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 159
10.4.6 REST OF ASIA PACIFIC 159
TABLE 156 REST OF APAC: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 160
TABLE 157 REST OF APAC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 158 REST OF APAC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 159 REST OF APAC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 161
10.5 LATIN AMERICA 161
TABLE 160 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 161
TABLE 161 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 162
TABLE 162 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 163 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 164 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 165 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 163
TABLE 166 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 164
TABLE 167 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 164
10.5.1 BRAZIL 164
10.5.1.1 Brazil is a key market in Latin America owing to the modernization of healthcare facilities 164
TABLE 168 BRAZIL: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 165
TABLE 169 BRAZIL: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 170 BRAZIL : EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 171 BRAZIL: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 166
10.5.2 MEXICO 166
10.5.2.1 Availability of advanced care and increasing awareness programs are driving market growth in Mexico 166
TABLE 172 MEXICO: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 167
TABLE 173 MEXICO: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 174 MEXICO: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 175 MEXICO: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 168
10.5.3 REST OF LATIN AMERICA 168
TABLE 176 REST OF LATAM: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 168
TABLE 177 REST OF LATAM: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 169
TABLE 178 REST OF LATAM: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 169
TABLE 179 REST OF LATAM: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2019–2026 (USD MILLION) 169
10.6 MIDDLE EAST & AFRICA 170
10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN THE MEA 170
TABLE 180 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 171
TABLE 181 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 171
TABLE 182 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS,
BY TYPE, 2019–2026 (USD MILLION) 171
TABLE 183 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 172
TABLE 184 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 172
TABLE 185 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 173
TABLE 186 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 173
11 COMPETITIVE LANDSCAPE 174
11.1 OVERVIEW 174
FIGURE 23 KEY DEVELOPMENTS IN THE EMBOLOTHERAPY MARKET FROM 2017 TO 2020 174
11.2 GLOBAL MARKET SHARE ANALYSIS 175
11.2.1 GLOBAL EMBOLOTHERAPY MARKET SHARE ANALYSIS (2019) 175
FIGURE 24 GLOBAL EMBOLOTHERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 175
11.3 COMPETITIVE LEADERSHIP MAPPING 175
11.3.1 STARS 176
11.3.2 EMERGING LEADERS 176
11.3.3 PERVASIVE 176
11.3.4 PARTICIPANTS 176
FIGURE 25 EMBOLOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020) 177
FIGURE 26 EMBOLOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (SME/START-UPS) 178
11.4 COMPETITIVE SCENARIO 179
11.4.1 PRODUCT LAUNCHES 179
TABLE 187 EMBOLOTHERAPY MARKET: PRODUCT LAUNCHES
AND APPROVALS, 2017–2020 179
11.4.2 EXPANSIONS 180
TABLE 188 EMBOLOTHERAPY MARKET: EXPANSIONS, 2017–2020 180
11.4.3 ACQUISITIONS 180
TABLE 189 EMBOLOTHERAPY MARKET: ACQUISITIONS, 2017–2020 180
12 COMPANY PROFILES 181
(Business Overview, Products Offered, Recent Developments, and MnM View)*
12.1 KEY PLAYERS 181
12.1.1 BOSTON SCIENTIFIC CORPORATION 181
TABLE 190 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW 181
FIGURE 27 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 182
12.1.2 MERIT MEDICAL SYSTEMS 185
TABLE 191 MERIT MEDICAL SYSTEMS: BUSINESS OVERVIEW 185
FIGURE 28 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT 186
12.1.3 TERUMO CORPORATION 188
TABLE 192 TERUMO CORPORATION: BUSINESS OVERVIEW 188
FIGURE 29 TERUMO CORPORATION: COMPANY SNAPSHOT 189
12.1.4 MEDTRONIC PLC 192
TABLE 193 MEDTRONIC PLC: BUSINESS OVERVIEW 192
FIGURE 30 MEDTRONIC PLC: COMPANY SNAPSHOT 192
12.1.5 ABBOTT LABORATORIES 195
TABLE 194 ABBOTT LABORATORIES: BUSINESS OVERVIEW 195
FIGURE 31 ABBOTT LABORATORIES: COMPANY SNAPSHOT 196
12.1.6 DEPUY SYNTHES (J&J MEDICAL DEVICES) 197
TABLE 195 DEPUY SYNTHES: BUSINESS OVERVIEW 197
FIGURE 32 JOHNSON & JOHNSON: COMPANY SNAPSHOT 198
12.1.7 COOK MEDICAL 200
TABLE 196 COOK MEDICAL: BUSINESS OVERVIEW 200
12.1.8 BALT 202
TABLE 197 BALT: BUSINESS OVERVIEW 202
12.1.9 SIRTEX MEDICAL LIMITED (PART OF CDH INVESTMENTS) 204
TABLE 198 SIRTEX MEDICAL LIMITED: BUSINESS OVERVIEW 204
12.1.10 KANEKA CORPORATION 205
TABLE 199 KANEKA CORPORATION: BUSINESS OVERVIEW 205
FIGURE 33 KANEKA CORPORATION: COMPANY SNAPSHOT 206
12.1.11 STRYKER CORPORATION 208
TABLE 200 STRYKER CORPORATION: BUSINESS OVERVIEW 208
FIGURE 34 STRYKER CORPORATION: COMPANY SNAPSHOT 208
12.2 OTHER PLAYERS 210
12.2.1 PENUMBRA, INC. 210
TABLE 201 PENUMBRA, INC.: BUSINESS OVERVIEW 210
FIGURE 35 PENUMBRA, INC.: COMPANY SNAPSHOT 211
12.2.2 MERIL LIFE SCIENCES PVT., LTD. 213
TABLE 202 MERIL LIFE SCIENCES PVT., LTD.: BUSINESS OVERVIEW 213
12.2.3 ACANDIS GMBH 214
TABLE 203 ACANDIS GMBH: BUSINESS OVERVIEW 214
12.2.4 CARDIVA MEDICAL INC. (PART OF HAEMONETICS) 215
TABLE 204 CARDIVA MEDICAL INC.: BUSINESS OVERVIEW 215
12.2.5 SHAPE MEMORY MEDICAL, INC. 216
TABLE 205 SHAPE MEMORY MEDICAL, INC..: BUSINESS OVERVIEW 216
12.2.6 ARTIO MEDICAL, INC. 217
TABLE 206 ARTIO MEDICAL, INC.: BUSINESS OVERVIEW 217
12.2.7 RAPID MEDICAL 218
TABLE 207 RAPID MEDICAL: BUSINESS OVERVIEW 218
12.2.8 IMBIOTECHNOLOGIES LTD. 219
TABLE 208 IMBIOTECHNOLOGIES LTD.: BUSINESS OVERVIEW 219
12.2.9 EMBOLINE, INC. 221
TABLE 209 EMBOLINE, INC.: BUSINESS OVERVIEW 221
*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13 APPENDIX 222
13.1 DISCUSSION GUIDE 222
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 227
13.3 AVAILABLE CUSTOMIZATIONS 229
13.4 RELATED REPORTS 229
13.5 AUTHOR DETAILS 230



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(MD7279 )"世界の動脈塞栓術市場(~2026年):製品別(塞栓剤(マイクロスフィア、液体塞栓剤、コイル)、マイクロカテーテル)、疾患別(腫瘍、血管、動脈瘤、泌尿器、腎臓)、処置別(TACE、TARE)、エンドユーザー別(病院、クリニック、ASC)" (英文:Embolotherapy Market by Product (Embolic Agents (Microspheres, Liquid Embolic Agents, Coil), Microcatheters), Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology), Procedure (TACE, TARE), Enduser (Hospital, Clinics, ASC) - Global Forecast to 2026)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。